Viewing Study NCT04844684



Ignite Creation Date: 2024-05-06 @ 4:01 PM
Last Modification Date: 2024-10-26 @ 2:02 PM
Study NCT ID: NCT04844684
Status: UNKNOWN
Last Update Posted: 2022-03-17
First Post: 2021-04-13

Brief Title: Evaluation of Cortisol and Bile Acids Metabolism in Obese Patients
Sponsor: University Hospital Lille
Organization: University Hospital Lille

Study Overview

Official Title: Link Between the Metabolism of Cortisol and Bile Acids in Obese Patients Before and After Bariatric Surgery
Status: UNKNOWN
Status Verified Date: 2022-03
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CORTABO
Brief Summary: Bariatric surgery is currently the most efficient treatment for obesity The sustained weight loss and metabolic improvement seen following Roux-en-Y gastric bypass RYGB is explained partly by modifications in hormones including bile acids BA After RYGB an increased total BA pool and a reduction in hepatic cortisol exposure is observed Hydroxysteroid 11-β dehydrogenase 1 HSD11B1 steroid 5α-reductases SRD5A and steroid 5β-reductases AKR1D1 also a BA metabolizing enzyme are three enzymes involved in the metabolism of cortisol in the liver and are known to participate in metabolic syndrome Their activity has been shown to be decreased after RYGB Interestingly the mechanisms explaining the modification of hepatic cortisol exposure and the activity of theses enzymes after RYGB are unknown In view of the few data suggesting a link between cortisol metabolism and bile acids this work aim to study and characterize this link in a context of RYBP
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2020-A03176-33 OTHER ID-RCB numberANSM None